Black Hawk Deal with Vesicor Therapeutics. Integrated Rail & Resources and Rigel Resource Set Extension Votes. Healthcare AI Acquisition Adjourns Vote to April 30.
Boardroom Alpha SPAC Resources
– Full SPAC Listing
– SPAC SEC Filings
– Boardroom Alpha IPO & SPAC Intelligence Platform (7-Day Trial)
Daily SPAC Update
SPAC DEAL & EXTENSION VOTES SET
IRRX – Integrated Rail & Resources Acquisition Corp * EXTENSION VOTE SET: May 13, 2025
RRAC – Rigel Resource Acquisition Corp * EXTENSION VOTE SET: May 08, 2025 * trust $11.84
OTHER SPAC NEWS
CITE – CARTICA ACQUISITION CORP * Auditor Change
BKHA – BLACK HAWK ACQUISITION CORP * Merger Agreement
CEP – CANTOR EQUITY PARTNERS INC * Merger Agreement
HAIA – HEALTHCARE AI ACQUISITION CORP * Vote Adjourned
NEW SPAC IPOs
Apr 24: CHAC – Crane Harbor Acquisition Corp. $200M IPO (+underwriter overallotment: $20M)
Apr 24: IPCX – Inflection Point Acquisition Corp. Iii $220M IPO (+underwriter overallotment: $33M)
Apr 23: NPAC – New Providence Acquisition Corp. Iii $261M IPO (+underwriter overallotment: $39.15M)
SPAC DEALS ANNOUNCED
Apr 28 | BKHA – Black Hawk Acquisition Corp + Vesicor Therapeutics, Inc.
ABOUT Vesicor Therapeutics, Inc.
Vesicor was founded in 2008 in San Gabriel, California by Luo Feng, Ph.D. The Company is an early development stage biotechnology company focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles.
The Company’s first product candidate is ecm-RV/p53. This is a genetically engineered cellular microvesicle (“ecm”) non-viral nanoparticle RNA vesicle (“RV”) that is loaded with in vitro transcribed p53 mRNA. Although Vesicor’s ecm-RV/p53 drug candidate is unapproved for use in Japan and the United States, it has been administered to multiple patients in Tokyo, Japan since 2018 under the Japan Medical Practitioner’s Act, also known as Advanced Medical Care B. This mechanism allows unapproved drugs to be used under a physician’s discretion. The Company’s drug candidate has been used in multiple patients with advanced breast, pancreatic, prostate, lung and colorectal cancer. Vesicor believes that its ecm-RV/p53 drug candidate has broad therapeutic potential across a range of solid tumors. The Company intends to begin preclinical testing in the U.S., submit an investigational new drug (“IND”) application to the FDA and then to begin clinical trials, which efforts are expected to commence in 2026.
SPAC DEAL TERMINATIONS (Last 10 Days)
20205-04-18: FSHP + Great Rich Technologies Limited
SPAC MOVERS
YESTERDAY’S TOP SPAC GAINERS
15.74% ~ $ 13.31 | CLBR – COLOMBIER ACQUISITION CORP II (Announced)
14.59% ~ $ 14.22 | BUJA – BUKIT JALIL GLOBAL ACQUISITION 1 LTD (Announced)
10.25% ~ $ 12.80 | DIST – DISTOKEN ACQUISITION CORP (Announced)
7.56% ~ $ 11.67 | HCVI – HENNESSY CAPITAL INVESTMENT CORP VI (Announced)
4.08% ~ $ 11.99 | TBMC – TRAILBLAZER MERGER CORP I (Announced)
YESTERDAY’S TOP SPAC LOSERS
-9.95% ~ $ 11.50 | MSSA – METAL SKY STAR ACQUISITION CORP (Pre-Deal)
-8.46% ~ $ 9.85 | BOWN – BOWEN ACQUISITION CORP (Announced)
-5.93% ~ $ 11.43 | DECA – DENALI CAPITAL ACQUISITION CORP (Announced)
-2.36% ~ $ 11.18 | YOTA – YOTTA ACQUISITION CORP (Announced)
-1.45% ~ $ 12.91 | DMYY – DMY SQUARED TECHNOLOGY GROUP INC (Pre-Deal)
LATEST SPAC IPO PERFORMANCE
Apr 24 | $ 9.99 | CHAC – Crane Harbor Acquisition Corp.
Apr 24 | $ 10.12 | IPCX – Inflection Point Acquisition Corp. III
Apr 23 | $ 10.09 | NPAC – New Providence Acquisition Corp. III
Apr 22 | $ 9.99 | TVA – Texas Ventures Acquisition III Corp
Apr 10 | $ 10.03 | TACH – Titan Acquisition Corp.
Apr 03 | $ 10.02 | SZZL – Sizzle Acquisition Corp. II
Apr 03 | $ 10.00 | SOUL – Soulpower Acquisition Corp.
Apr 01 | $ 10.07 | SDHI – Siddhi Acquisition Corp
Mar 31 | $ 10.08 | UYSC – UY Scuti Acquisition Corp.